McGill, Yale and Universities of Pennsylvania and Massachusetts join PanFAM-1, the largest ever prospective multicenter clinical study for early detection of pancreatic cancer
New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancerLUND, SWEDEN ― Immunovia AB today announced that four additional North American Familial Pancreatic Cancer (FPC) sites are to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with heredity risk of pancreatic cancer. Designed to validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, PanFAM-1 study will analyze more than two thousand individuals